Building a shared sense of community helps create the relationships and interactions that bring people together and make teams and sector ecosystems successful. Community is a core part of building a distinctive culture. With a portfolio of related investments, industry

Neuroscience has quietly become a hot space for startups. Across a range of neurologic conditions, contrarian investors have been fueling entrepreneurs to discover and develop novel therapeutic strategies. Earlier this week, two Atlas-founded companies, Rodin Therapeutics and Disarm Therapeutics, both announced

Last month, Bloomberg bemoaned the dearth of biotech M&A, and pundits echoed the sentiment (here, here), citing concerns about tax rates and drug pricing. The top line numbers in Bloomberg’s graph certainly paint a dim view of 2017’s global biotech

It’s all about people, it always is. Human capital is a company’s most important asset. Successful companies have human capital management strategies that excel at talent recruitment, and prioritize career development and retention. But human capital is never static, and

This blog was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC. On my first morning as a US-based employee, I took advantage of the hotel’s shopping service by ordering the

Today BMS announced the acquisition of IFM Therapeutics, an emerging biotech focused on modulating core innate immune pathways to treat cancer and autoimmune disease. As described in the press release, BMS will acquire the company for $300M upfront, with potentially

Corporate culture is often hard to precisely define. Yet it’s always cited as being one of the key drivers of company outperformance, especially for startups. Recently I was asked to define what culture means by a young entrepreneur: beyond the

Today we announced the closing of Atlas Venture Fund XI, a $350M investment vehicle focused exclusively on early stage biotech investing. Since launching our fundraising process in April, we’ve received a truly humbling level of support and interest in our

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC. Much has been said about who and when to hire in this blog (here and here for example), but

This blog was written by Michael Gladstone, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC. The 2017 American Society of Clinical Oncology (“ASCO”) meeting concluded last week, providing patients, physicians, and industry stakeholders with

This blog was written by Brian Fenton and Paul Burgess, CBO and GC of RaNA Therapeutics, respectively, as part of the From The Trenches feature of LifeSciVC.  On April 18, 1775, Paul Revere was summoned by Dr. Joseph Warren of

We’re excited to announce Kevin Bitterman has joined Atlas Venture as a partner! Kevin is well known in the Boston biotech ecosystem, having spent the last dozen-plus years on the life science team at Polaris Partners. He brings a great